Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Q1 2025 earnings

Reported May 15, 2025 · Before market open

Revenue$2.3MBeat by $1.2M
EPS-$0.08In line
Revenue estimate$1.1M
EPS estimate-$0.08

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$755.6K
EPS estimate-$0.14

Financials

Q1 2025

Income statement

See full
Revenue$2.3M-32.5%
Operating income-$21.4M+12.0%
Net income-$21.5M+10.5%
EPS (diluted)-$0.08+20.0%

Balance sheet

See full
Cash & equivalents$116.6M-6.0%
Total debt$61.6M+0.4%
Total equity$55.1M+2.2%
Total assets$138.4M-9.6%

Cash flow

See full
Operating cash flow-$22.0M-11.2%
CapEx$378.0K+170%
Free cash flow-$22.4M-12.3%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$284.95M-50.7%
Enterprise value$229.99M-55.4%
P/S39.4×-1.4×

Profitability

See full
Operating margin-1,225.8%-8,731pp
Net margin-1,201.1%—
FCF margin-1,163.6%-5,563pp

Returns & leverage

See full
Return on equity-159.3%—
Debt / equity1.1×0.0×
Current ratio5.4×+2.0×

FAQ

When did Taysha Gene Therapies, Inc. report Q1 2025 earnings?
Taysha Gene Therapies, Inc. (TSHA) reported Q1 2025 earnings on May 15, 2025 before market open.
What were Taysha Gene Therapies, Inc.'s Q1 2025 revenue and EPS?
Taysha Gene Therapies, Inc. reported revenue of $2.3M and eps of $-0.08 for Q1 2025.
Did Taysha Gene Therapies, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $1.1M by $1.2M. EPS beat the consensus estimate of $-0.08 by $0.00.
How did Taysha Gene Therapies, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 32.5% from $3.4M a year earlier and eps grew 20.0% from $-0.10.
Where can I find Taysha Gene Therapies, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-120329) and the 10-Q periodic report (0000950170-25-072036) directly on SEC EDGAR. The filing index links above go to sec.gov.